Drugs / Nandrolone Decanoate
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DECA-DURABOLIN | — | 1962-10-05 | fda.gov ↗ |
Trials 12
1961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00000854 | ? → May 2003 | HIV wasting syndrome | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02055456 | Feb 2014 → Feb 2017 | aplastic anemia, bone marrow failure syndrome, idiopathic pulmonary fibrosis, telomere syndrome | University of Sao Paulo | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT05978206 | Aug 2023 → Dec 2026 expected | muscular atrophy | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | Recruiting | No outcome recorded |
| Phase 2 | NCT03545347 | Sep 2018 → May 2020 | bone disorder | Morten Tange Kristensen PT, PhD | Completed | Missed primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT06462482 | Jan 2025 → Aug 2026 overdue | — | American Hip Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06608914 | Jan 2025 → Nov 2026 expected | osteoarthritis, hip | American Hip Institute | Not yet recruiting | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07568574 | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
| — | NCT05805553 | Dec 2020 → Sep 2023 | disease of bone structure | King Edward Medical University | Unknown | No outcome recorded |
| — | NCT03588767 | May 2017 → May 2020 | nervous system injury | University Hospital Ostrava | Completed | No outcome recorded |
| — | NCT03263520 | Feb 2016 → Aug 2017 | hypoproteinemia, hypercatabolic | Hospital Erasto Gaertner | Completed | No outcome recorded |
| — | NCT02376309 | Aug 2015 → Aug 2016 | muscular atrophy | Maastricht University Medical Center | Completed | No outcome recorded |
| — | NCT00250536 | Mar 2000 → Oct 2004 | end stage renal failure | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nandrolone Decanoate | “such as nandrolone decanoate (Deca-Durabolin) already on the first day” NCT03588767 ↗11“1 nandrolone decanoate injection” NCT02376309 ↗ |
| Known as | Deca-Durabolin | “such as nandrolone decanoate (Deca-Durabolin) already on the first day” NCT03588767 ↗1“Nandrolone Decanoate (Deca-Durabolin)” NCT07568574 ↗ |
| Known as | Nandrolone decanoate ciii | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200946 ↗ |
| Action | Activate | “Androgen Receptor agonist” CHEMBL1200946 ↗ |
| Modality | Small molecule | “anabolic steroid” NCT03263520 ↗ |
| Route | Intramuscular | “by weekly intramuscular injection” NCT00250536 ↗ |
| Target | AR | “Androgen Receptor agonist” CHEMBL1200946 ↗ |